The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment

Thrombosis Research

Volumn 131, Issue 2, 2013, Pages 125-129

  Skov, Jane ^a   Bladbjerg, Else Marie ^a   Leppin, Anja ^a   Jespersen, Jørgen ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

anticoagulant clinic; INR; pharmacogenetics; warfarin

Indexed keywords

CYTOCHROME P450 2C9; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PATIENT SAFETY; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PROSPECTIVE STUDIES; WARFARIN;

EID: 84872326611     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.11.004     Document Type: Article

References (30)

1. R.L. Seip, J. Duconge, and G. Ruano Implementing genotype-guided antithrombotic therapy Future Cardiol 6 2010 409 424
2. M. Pirmohamed Warfarin: almost 60 years old and still causing problems Br J Clin Pharmacol 62 5 2006 509 511
3. M. Moridani, L. Fu, R. Selby, F. Yun, T. Sukovic, and B. Wong Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort Clin Biochem 39 6 2006 606 612
4. C. Geisen, M. Watzka, K. Sittinger, M. Steffens, L. Daugela, and E. Seifried VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation Thromb Haemost 94 4 2005 773 779
5. M. Wadelius, L.Y. Chen, J.D. Lindh, N. Eriksson, M.J. Ghori, and S. Bumpstead The largest prospective warfarin-treated cohort supports genetic forecasting Blood 113 2009 784 792
6. T. Schalekamp, B.P. Brasse, J.F. Roijers, E. van Meegen, F.J. van der Meer, and E.M. van Wijk VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement Clin Pharmacol Ther 81 2007 185 193
7. L. Bodin, C. Verstuyft, D.A. Tregouet, A. Robert, L. Dubert, and C. Funck-Brentano Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity Blood 106 2005 135 140
8. M. Beinema, J.R. Brouwers, T. Schalekamp, and B. Wilffert Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon Thromb Haemost 100 2008 1052 1057
9. N. Ferder, C.S. Eby, E. Deych, J.K. Harris, P.M. Ridker, and P. Milligan Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy J Thromb Haemost 8 1 2010 95 100
10. B.D. Horne, P.A. Lenzini, M. Wadelius, A.L. Jorgensen, S.E. Kimmel, and P.M. Ridker Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy Thromb Haemost 107 2012 232 240
11. B.F. Gage, C. Eby, J.A. Johnson, E. Deych, M.J. Rieder, and P.M. Ridker Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin Clin Pharmacol Ther 84 2008 326 331
12. T.I. Verhoef, W.K. Redekop, M.M. Buikema, T. Schalekamp, F.J. van der Meer, and S. le Cessie Long-term anticoagulant effects of CYP2C9 and VKORC1 genotype in acenocoumarol users J Thromb Haemost 10 2012 606 614
13. K.N. Kangelaris, S. Bent, R.L. Nussbaum, D.A. Garcia, and J.A. Tice Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin J Gen Intern Med 24 2009 656 664
14. J.K. Burmester, R.L. Berg, S.H. Yale, C.M. Rottscheit, I.E. Glurich, and J.R. Schmelzer A randomized controlled trial of genotype-based Coumadin initiation Genet Med 13 2011 509 518
15. J.L. Anderson, B.D. Horne, S.M. Stevens, S.C. Woller, K.M. Samuelson, and J.W. Mansfield A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II) Circulation 125 2012 1997 2005
16. E. Hummers-Pradier, S. Hess, I.M. Adham, T. Papke, B. Pieske, and M.M. Kochen Determination of bleeding risk using genetic markers in patients taking phenprocoumon Eur J Clin Pharmacol 59 2003 213 219
17. L.E. Visser, R.H. van Schaik, M. van Vliet, P.H. Trienekens, P.A. De Smet, and A.G. Vulto The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon Thromb Haemost 92 2004 61 66
18. L. Poller, M. Keown, S. Ibrahim, G. Lowe, M. Moia, and A.G. Turpie A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program Thromb Haemost 101 2009 487 494
19. J.L. Dorsey Software support for 'doing the right thing right' Thromb Haemost 101 2009 413 414
20. J. Skov, A. Leppin, E.M. Bladbjerg, J. Sidelmann, and J. Gram Perceived stress predicts the stability of vitamin K-antagonist treatment of anticoagulant clinic patients Thromb Haemost 108 2012 581 582
21. J. Skov, E.M. Bladbjerg, J. Sidelmann, M. Vamosi, and J. Jespersen Plenty of pills: polypharmacy prevails in patients of a Danish anticoagulant clinic Eur J Clin Pharmacol 67 2011 1169 1174
22. M.A. Rasmussen, J. Skov, E.M. Bladbjerg, J.J. Sidelmann, M. Vamosi, and J. Jespersen Multivariate analysis of the relation between diet and warfarin dose Eur J Clin Pharmacol 68 2012 321 328
23. J. Skov, E.M. Bladbjerg, M.A. Rasmussen, J.J. Sidelmann, A. Leppin, and J. Jespersen Genetic, clinical and behavioral determinants of vitamin K-antagonist dose - explored through multivariable modelling and visualization Basic Clin Pharmacol Toxicol 110 2012 193 198
24. E. Hatch, E.A. Sconce, A.K. Daly, and F. Kamali A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene J Thromb Haemost 4 2006 1158 1159
25. F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, and E. Briet A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 1993 236 239
26. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
27. R.M. van Schie, A.M. Babajeff, T. Schalekamp, J.A. Wessels, S. le Cessie, and A. de Boer An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol J Thromb Haemost 10 2012 767 772
28. A.J. Rose, E.M. Hylek, A. Ozonoff, A.S. Ash, J.I. Reisman, and D.R. Berlowitz Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA) J Thromb Haemost 8 2010 2182 2191
29. L. Wallentin, S. Yusuf, M.D. Ezekowitz, M. Alings, M. Flather, and M.G. Franzosi Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
30. H.D. White, M. Gruber, J. Feyzi, S. Kaatz, H.F. Tse, and S. Husted Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V Arch Intern Med 167 2007 239 245